216661-58-4

Basic information

• Product Name: Pyrazolo[1,5-a]pyrimidine, 6-(4-methoxyphenyl)-3-(4-pyridinyl)-
• CAS NO: 216661-58-4
• Molecular Formula: C18H14N4O
• Molecular Weight: 302.335
• Mol File: 216661-58-4.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Pyrazolo[1,5-a]pyrimidine, 6-(4-methoxyphenyl)-3-(4-pyridinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrazolo[1,5-a]pyrimidine, 6-(4-methoxyphenyl)-3-(4-pyridinyl)-(216661-58-4)
• EPA Substance Registry System: Pyrazolo[1,5-a]pyrimidine, 6-(4-methoxyphenyl)-3-(4-pyridinyl)-(216661-58-4)

Safety Data

• Hazardous Substances Data: 216661-58-4(Hazardous Substances Data)

Upstream product

• 53868-40-9 2-(4-methoxyphenyl)-3-malonaldehyde 
• 216661-87-9 5-amino-4-(pyridin-4-yl)-1H-pyrazole 
• 100-09-4 4-methoxybenzoic acid 
• 10445-91-7 4-(Chloromethyl)pyridine 
• 103851-89-4 3-(dimethylamino)-2-(4-pyridyl)prop-2-enenitrile 
• 92333-25-0 pyridin-4-ylacetonitrile hydrochloride 
• 1692-15-5 4-pyridylboronic acid 
• 216661-83-5 3-(bromo)-6-(4-methoxyphenyl)-pyrazolo(1,5-A)pyrimidine 
• 945376-95-4 4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenol 
• 216661-87-9 4-(4-pyridyl)-1H-pyrazol-3-amine 
• 65192-28-1 2-(4-methoxyphenyl)malondialdehyde 
• 493038-83-8 (Z)-3-(dimethylamino)-2-(4-pyridyl)prop-2-enenitrile 
• 13121-99-8 pyridin-4-ylacetonitrile 

Downstream Products

• 1450754-58-1 6-(4-(2-(3-(but-3-ynyl)-3H-diazirin-3-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine 
• 1062368-41-5 6-{4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-3-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine 
• 866405-64-3 dorsomorphin 
• 597544-21-3 4-(2-(4-(3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenoxy)ethyl)morpholine 
• 515880-87-2 6-(4-hydroxyphenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine 

Relevant articles and documents

Inhibitor of heat shock factor 1, and preparation method and application of inhibitor

The invention provides an inhibitor of a heat shock factor 1 (HSF1) and an application of the inhibitor, particularly a compound as shown in a formula I or pharmaceutically-acceptable salt of the compound. The compound has excellent HSF1 restraining activity and tumor resisting effects. The invention further provides a medical composition containing the compound and an application of the medical composition in the respect of restraining HSF1.

INHIBITORS OF THE BMP SIGNALING PATHWAY

The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.

Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors

A structure-activity relationship study of dorsomorphin, a previously identified inhibitor of SMAD 1/5/8 phosphorylation by bone morphogenetic protein (BMP) type 1 receptors ALK2, 3, and 6, revealed that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine ring with 4-quinoline. The activity contributions of various nitrogen atoms in the core pyrazolo[1,5-a]pyrimidine ring were also examined by preparing and evaluating pyrrolo[1,2-a]pyrimidine and pyrazolo[1,5-a]pyridine derivatives. In addition, increased mouse liver microsome stability was achieved by replacing the ether substituent on the pendent phenyl ring with piperazine. Finally, an optimized compound 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic characteristics (e.g., plasma t1/2 = 1.6 h) following intraperitoneal administration in mice. These studies provide useful molecular probes for examining the in vivo pharmacology of BMP signaling inhibition.